Teclison, a Princeton, NJ-based clinical-stage biotechnology company developing innovative cancer therapeutics to induce tumor necrosis and enhance anti-tumor immunity, closed a $5.9m funding round.
The round was led by W.T.T. Investment, the family office of Taiwan’s Tsai family, with participation from new and existing U.S. and Taiwan investors, including Nestor Capital.
The company intends to use the proceeds from the financing to further advance clinical studies of its lead product candidate, TEC-001, a potential first-in-class therapeutic agent designed to induce tumor necrosis and enhance immune checkpoint inhibitors in solid cancers with liver metastasis.
Led by Ray Lee, M.D., Ph.D., Founder and CEO, Teclison is a clinical-stage biotechnology company developing innovative cancer therapeutics to induce tumor necrosis and enhance anti-tumor immunity. The company’s portfolio is comprised of new approaches aimed at enhancing the therapeutic benefit of tumor embolization and immunotherapy to treat nearly all solid cancers. Its therapeutic platform, Trans-Arterial TEC-001 Embolization (“TATE”), is being evaluated both as a monotherapy and in combination with FDA-approved immune checkpoint inhibitors in Phase 2 clinical trials for liver, colorectal, and lung cancers.
FinSMEs
14/02/2022